Eleusis SPAC

Third Party Oral Psilocybin Proof of Concept Studies in MDD and Treatment Resistant Depression (TRD) Rapid, robust, and durable efficacy observed MDD Clinical Study: Psilocybin (25mg) vs. Escitalopram¹ Met Primary Endpoint No statistically significant difference in QIDS- SR-16 depression score at 6 weeks, but assessments favored psilocybin² Secondary outcomes² Mean Change (QIDS-SR-16 Score) include: MADRS: HAM-D-17: -14.4 vs -7.2 -10.5 vs -5.1 0.0- -2.5- -5.0- -7.5- -10.0- 0 7 "A series of studies by Carhart-Harris and colleagues...provide tantalizing evidence for the efficacy of psilocybin in the treatment of major depressive disorder" 3 Prof Jeffery Lieberman, Columbia University Psilocybin 14 21 Day Escitalopram 28 35 H 42 - LS mean change from baseline in MADRS total score MADRS: -6.6 "We now have evidence from a large well-designed trial that psilocybin may be effective for people with (p<.001; 25mg vs 1mg) treatment-resistant major depressive disorder” 5 -8 -10 -12 -14 but significant room for improvement -16 TRD Phase IIb Study: Psilocybin (25mg, 10mg, 1mg)4 Significant Effect from Day 2 to Week 6 Reported in Third Party Topline Data Release Day-1 Prof David Hellerstein, Principal Investigator, Columbia University Day 2 * Week 1 Week 6 COMP360 25mg --COMP360 10mg -COMP360 1mg Baseline mean (SD): 25mg (n=79) = 31.9 (5.41); 10mg (n=75)= 33.0 (6.31); 1mg (n=79) = 32.7 (6.24) Week 3: 25mg Diff = -6.6, p = <0.001 vs 1mg 10mg Diff = -2.5, p = 0.184 Week 3 Week 9 Week 12 Source: 1) Carhart-Harris et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402-1411; psilocybin dosing at day 0, 21; escitalopram group received 2 separate doses of 1 mg of psilocybin plus daily escitalopram 2) As per Carhart-Harris et al. (2021), statistical significance assessments not conducted other than for primary endpoint at 6-week timepoint, and no correction for multiple comparisons of the outcomes was conducted at any intermediate time points, so no clinical conclusions can be drawn. 3) Lieberman, J. (2021) Back to the Future - The Therapeutic Potential of Psychedelic Drugs, NEJM 384,15.4_15_2021; 4) COMPASS Pathways Press Release, 11/9/2021; and COMPASS Pathways Phase IIb Trial Presentation 11/9/20215) https://www.columbiapsychiatry.org/news/psilocybin-found-rapidly-improve-depressive-symptoms-clinical-trial 11

View entire presentation